CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therape ...

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), dosing its first patient in a Phase I clinical trialPresented preclinical activity of icovamenib in combination with semaglutide in type 2 diabetes (“T2D”) animal model at EASD Annual Meeting, demonstrating enhanced glycemic control and body weight reduction with preservation of lean massR ...

Strong Portfolio Momentum Continues to be Driven by AI and AI Infrastructure Investments Net Asset Value of $9.23 Per Share as of September 30, 2025 Board of Directors Declares $0.25 Per Share Cash Dividend NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the third quarter ended September 30, 2025. Net assets totaled approximately $231.8 million, or $9.23 per share, at September 30, ...

New luxury home community offers two collections of single-family homes with exceptional amenitiesLEANDER, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the opening of its newest community, Wildspring by Toll Brothers, in Leander, Texas. This new community features two collections of thoughtfully designed single-family homes with outstanding personalization options, situated within the highly rated Leander Independent S ...

SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $44.4 million ...

Sequential Quarterly Increase in Gross Margins; Continued Program Wins; Positive Cash Flow from Operations SPOKANE VALLEY, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Key Tronic Corporation (Nasdaq: KTCC), a provider of electronic manufacturing services (EMS), today announced its results for the quarter ended September 27, 2025. For the first quarter of fiscal year 2026, Key Tronic reported total revenue of $98.8 million, compared to $131.6 million in the same period of fiscal year 2025. The revenue for the f ...

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to ...

Q1 FY26 Bookings of $250.2 million; book-to-bill of 1.11Record backlog of $1.4 billion; up 6.5% year-over-yearQ1 FY26 Revenue of $225.2 million, up 10.2% year-over-year; GAAP net loss of $12.5 million; and adjusted EBITDA of $35.6 million, up 66% year-over-yearQ1 FY26 Operating Cash Flow of $2.2 million with Free Cash Flow of $(4.4) million ANDOVER, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), reported operating results for the first quarter of fiscal year 202 ...

Solid third quarter results enabling the company to narrow it 2025 financial guidance rangeSponsor-enabled growth and repowerings for 2026/2027 COD on track with over 2 GW of projects now on identified opportunities listSigned binding 3rd party M&A agreement for operational solar portfolio Opportunistically raised $50MM of equity through equity issuance program PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) today reported third quarter 2025 financial results, ...

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD with potential for indication-leading efficacy, safety, and dosing profiles SPY003 expected to advance to the ongoing Part A of the SKYLINE Ph2 platform trial SKYLINE and SKYWAY trials are expected to provide 6 proof-of-concept readouts ...